Brokerages Expect Leap Therapeutics Inc (LPTX) to Post ($0.51) EPS

Leap Therapeutics Inc (NASDAQ:LPTX) has received a consensus broker rating score of 1.50 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has assigned a strong buy rating to the company.

Brokers have set a 1-year consensus target price of $15.50 for the company and are forecasting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Leap Therapeutics an industry rank of 195 out of 265 based on the ratings given to related companies.

Get Leap Therapeutics alerts:

Separately, Zacks Investment Research raised Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Tuesday, January 9th.

Shares of Leap Therapeutics (LPTX) traded down $0.03 during trading on Thursday, reaching $7.22. The company had a trading volume of 139,711 shares, compared to its average volume of 62,564. Leap Therapeutics has a 1 year low of $4.90 and a 1 year high of $9.36.

An institutional investor recently bought a new position in Leap Therapeutics stock. Sabby Management LLC bought a new stake in shares of Leap Therapeutics Inc (NASDAQ:LPTX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned about 0.72% of Leap Therapeutics at the end of the most recent quarter. Institutional investors own 3.25% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Brokerages Expect Leap Therapeutics Inc (LPTX) to Post ($0.51) EPS” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://sportsperspectives.com/2018/03/11/brokerages-expect-leap-therapeutics-inc-lptx-to-post-0-51-eps.html.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).